Efficient expansion of rare human circulating hematopoietic stem/progenitor cells in steady-state blood using a polypeptide-forming 3D culture.

Efficient expansion of rare human circulating hematopoietic stem/progenitor cells in steady-state blood using a polypeptide-forming 3D culture.
复制标题

使用形成多肽的 3D 培养物有效扩增稳态血液中稀有的人类循环造血干/祖细胞

DOI:
10.1007/s13238-021-00900-4
复制
发表时间:
2022-11
期刊:
影响因子:
21.1
通讯作者:
Huang, He
Huang, He
中科院分区:
生物学1区
文献类型:
--
作者:
Xu, Yulin;Zeng, Xiangjun;Zhang, Mingming;Wang, Binsheng;Guo, Xin;Shan, Wei;Cai, Shuyang;Luo, Qian;Li, Honghu;Li, Xia;Li, Xue;Zhang, Hao;Wang, Limengmeng;Lin, Yu;Liu, Lizhen;Li, Yanwei;Zhang, Meng;Yu, Xiaohong;Qian, Pengxu;Huang, He

文献摘要

参考文献

相似文献

尽管造血干/祖细胞(HSPC)广泛应用于造血系统恶性肿瘤的治疗,但HSPC的短缺阻碍了HSPC的移植。稳态血液中的循环HSPCs(cHSPCs)是否可以用作替代来源仍然很难确定。本研究建立了一个包含精氨酸、甘氨酸、天冬氨酸等一系列因子的三维培养体系(3DCS)。外周血单个核细胞(PBMNCs)在3DCS中培养14天导致CD 34+细胞的频率和数量增加125倍和70倍。此外,与骨髓中的CD 34 + HSPC相比,3DCS扩增的cHSPC表现出相似的重建率。从机制上讲,3DCS构建了一个免疫调节小生境,分泌细胞因子如TNF,以支持cHSPC存活和增殖。最后,3DCS还可以促进HSPC动员失败的患者中cHSPC的扩增。我们的3DCS成功扩增了罕见的cHSPC,为HSPC治疗提供了替代来源,特别是对于HSPC动员失败的患者/供体。
Although widely applied in treating hematopoietic malignancies, transplantation of hematopoietic stem/progenitor cells (HSPCs) is impeded by HSPC shortage. Whether circulating HSPCs (cHSPCs) in steady-state blood could be used as an alternative source remains largely elusive. Here we develop a three-dimensional culture system (3DCS) including arginine, glycine, aspartate, and a series of factors. Fourteen-day culture of peripheral blood mononuclear cells (PBMNCs) in 3DCS led to 125- and 70-fold increase of the frequency and number of CD34+cells. Further, 3DCS-expanded cHSPCs exhibited the similar reconstitution rate compared to CD34+HSPCs in bone marrow. Mechanistically, 3DCS fabricated an immunomodulatory niche, secreting cytokines as TNF to support cHSPC survival and proliferation. Finally, 3DCS could also promote the expansion of cHSPCs in patients who failed in HSPC mobilization. Our 3DCS successfully expands rare cHSPCs, providing an alternative source for the HSPC therapy, particularly for the patients/donors who have failed in HSPC mobilization.
DOI: 10.1038/leu.2015.8
发表时间: 2015-06
期刊: Leukemia
影响因子: 11.4
作者:
通讯作者: --
DOI: 10.1073/pnas.86.22.8897
发表时间: 1989-11-01
影响因子: 11.1
作者:
BODINE, DM;KARLSSON, S;NIENHUIS, AW
通讯作者: NIENHUIS, AW
DOI: 10.1016/j.exphem.2004.06.010
发表时间: 2004-09-01
影响因子: 2.6
作者:
McKinney-Freeman, S;Goodell, MA
通讯作者: Goodell, MA
DOI: 10.1038/s41596-020-0292-x
发表时间: 2020-02-26
期刊: NATURE PROTOCOLS
影响因子: 14.8
作者:
Efremova, Mirjana;Vento-Tormo, Miquel;Vento-Tormo, Roser
通讯作者: Vento-Tormo, Roser
DOI: 10.1182/blood.v87.11.4544.bloodjournal87114544
发表时间: 1996-06-01
期刊: BLOOD
影响因子: 20.3
作者:
Ku, H;Yonemura, Y;Ogawa, M
通讯作者: Ogawa, M